Jennifer Domm is an Oncology physician affiliated with Sarah Cannon. OpenAlex indexes 67 publications with 2,821 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 23rd Ave N
Suite 450
Nashville, TN 372031534
Telephone
615-342-7339Registry record last updated 10 Feb 2022.
Industry payments
56 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202569 payments$85,081openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202512 payments
- CSL BehringProgram year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
56%Short-acting sulfonamides56%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsMetabolism & gastrointestinal
44%Proton pump inhibitor44%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-Thalassemia
Biology of Blood and Marrow Transplantation
2025 - Safety and Feasibility of Fertility Preservation and Fertility Outcomes in Patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Undergoing Gene Therapy
Biology of Blood and Marrow Transplantation
2025 - Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy
Biology of Blood and Marrow Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Hainsworth, MD
Sarah Cannon
William Liggett, MD
Sarah Cannon
Meredith Pelster, MD
Sarah Cannon
Dianna Shipley, MD
Sarah Cannon
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”